HAEMONETICS CORP/MASS (HAE) Stock Fundamental Analysis
NYSE:HAE - New York Stock Exchange, Inc. - US4050241003 - Common Stock
We assign a fundamental rating of 6 out of 10 to HAE. HAE was compared to 191 industry peers in the Health Care Equipment & Supplies industry. While HAE has a great profitability rating, there are some minor concerns on its financial health. HAE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year HAE was profitable.
HAE had a positive operating cash flow in the past year.
Each year in the past 5 years HAE has been profitable.
In the past 5 years HAE always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 4.90%, HAE belongs to the best of the industry, outperforming 83.68% of the companies in the same industry.
Looking at the Return On Equity, with a value of 14.09%, HAE belongs to the top of the industry, outperforming 88.42% of the companies in the same industry.
HAE's Return On Invested Capital of 7.59% is amongst the best of the industry. HAE outperforms 86.84% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HAE is in line with the industry average of 8.08%.
The 3 year average ROIC (7.51%) for HAE is below the current ROIC(7.59%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.9% | ||
| ROE | 14.09% | ||
| ROIC | 7.59% |
ROA(3y)4.55%
ROA(5y)4.81%
ROE(3y)10.72%
ROE(5y)11.21%
ROIC(3y)7.51%
ROIC(5y)8.04%
1.3 Margins
HAE has a better Profit Margin (9.10%) than 83.68% of its industry peers.
In the last couple of years the Profit Margin of HAE has grown nicely.
HAE's Operating Margin of 15.80% is amongst the best of the industry. HAE outperforms 86.32% of its industry peers.
In the last couple of years the Operating Margin of HAE has grown nicely.
HAE's Gross Margin of 54.02% is in line compared to the rest of the industry. HAE outperforms 47.37% of its industry peers.
In the last couple of years the Gross Margin of HAE has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.8% | ||
| PM (TTM) | 9.1% | ||
| GM | 54.02% |
OM growth 3Y24.43%
OM growth 5Y5.91%
PM growth 3Y-0.56%
PM growth 5Y9.58%
GM growth 3Y4.96%
GM growth 5Y3.61%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HAE is destroying value.
The number of shares outstanding for HAE has been increased compared to 1 year ago.
The number of shares outstanding for HAE has been reduced compared to 5 years ago.
HAE has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.69 indicates that HAE is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.69, HAE is doing good in the industry, outperforming 64.21% of the companies in the same industry.
HAE has a debt to FCF ratio of 39.37. This is a negative value and a sign of low solvency as HAE would need 39.37 years to pay back of all of its debts.
The Debt to FCF ratio of HAE (39.37) is better than 67.89% of its industry peers.
A Debt/Equity ratio of 1.39 is on the high side and indicates that HAE has dependencies on debt financing.
HAE has a Debt to Equity ratio of 1.39. This is amonst the worse of the industry: HAE underperforms 80.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.39 | ||
| Debt/FCF | 39.37 | ||
| Altman-Z | 2.69 |
ROIC/WACC0.92
WACC8.22%
2.3 Liquidity
A Current Ratio of 3.49 indicates that HAE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.49, HAE is in the better half of the industry, outperforming 63.68% of the companies in the same industry.
HAE has a Quick Ratio of 2.09. This indicates that HAE is financially healthy and has no problem in meeting its short term obligations.
HAE has a Quick ratio of 2.09. This is comparable to the rest of the industry: HAE outperforms 52.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.49 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
HAE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.48%, which is quite good.
HAE shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.74% yearly.
Looking at the last year, HAE shows a quite strong growth in Revenue. The Revenue has grown by 9.85% in the last year.
HAE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.23% yearly.
EPS 1Y (TTM)11.48%
EPS 3Y19.2%
EPS 5Y10.74%
EPS Q2Q%13.13%
Revenue 1Y (TTM)9.85%
Revenue growth 3Y14.57%
Revenue growth 5Y6.23%
Sales Q2Q%8.59%
3.2 Future
Based on estimates for the next years, HAE will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.65% on average per year.
HAE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.79% yearly.
EPS Next Y16.5%
EPS Next 2Y15.78%
EPS Next 3Y15.56%
EPS Next 5Y17.65%
Revenue Next Year7.65%
Revenue Next 2Y5.36%
Revenue Next 3Y6.59%
Revenue Next 5Y8.79%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 18.44, which indicates a rather expensive current valuation of HAE.
Based on the Price/Earnings ratio, HAE is valued cheaply inside the industry as 88.42% of the companies are valued more expensively.
HAE is valuated rather cheaply when we compare the Price/Earnings ratio to 28.29, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 14.10, which indicates a correct valuation of HAE.
91.05% of the companies in the same industry are more expensive than HAE, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.44, HAE is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.44 | ||
| Fwd PE | 14.1 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HAE is valued cheaper than 86.84% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HAE is valued a bit cheaper than the industry average as 68.42% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 121.44 | ||
| EV/EBITDA | 14.22 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
HAE has an outstanding profitability rating, which may justify a higher PE ratio.
HAE's earnings are expected to grow with 15.56% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.12
PEG (5Y)1.72
EPS Next 2Y15.78%
EPS Next 3Y15.56%
5. Dividend
5.1 Amount
HAE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HAEMONETICS CORP/MASS
NYSE:HAE (1/21/2025, 8:04:55 PM)
After market: 75.24 0 (0%)75.24
+1.75 (+2.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.5%
Inst Owner Change-0.1%
Ins Owners0.9%
Ins Owner Change-1.77%
Market Cap3.78B
Analysts81.43
Price Target113.02 (50.21%)
Short Float %10.51%
Short Ratio9.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.9%
Min EPS beat(2)0.44%
Max EPS beat(2)3.35%
EPS beat(4)3
Avg EPS beat(4)3.29%
Min EPS beat(4)-0.02%
Max EPS beat(4)9.38%
EPS beat(8)7
Avg EPS beat(8)9.85%
EPS beat(12)11
Avg EPS beat(12)11.14%
EPS beat(16)13
Avg EPS beat(16)8.25%
Revenue beat(2)0
Avg Revenue beat(2)-0.46%
Min Revenue beat(2)-0.76%
Max Revenue beat(2)-0.16%
Revenue beat(4)2
Avg Revenue beat(4)1.58%
Min Revenue beat(4)-0.76%
Max Revenue beat(4)3.94%
Revenue beat(8)6
Avg Revenue beat(8)2.11%
Revenue beat(12)9
Avg Revenue beat(12)2.42%
Revenue beat(16)11
Avg Revenue beat(16)2.29%
PT rev (1m)0%
PT rev (3m)0.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.59%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.44 | ||
| Fwd PE | 14.1 | ||
| P/S | 2.78 | ||
| P/FCF | 121.44 | ||
| P/OCF | 44.48 | ||
| P/B | 4.3 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.22 |
EPS(TTM)4.08
EY5.42%
EPS(NY)5.34
Fwd EY7.09%
FCF(TTM)0.62
FCFY0.82%
OCF(TTM)1.69
OCFY2.25%
SpS27.11
BVpS17.5
TBVpS-4.48
PEG (NY)1.12
PEG (5Y)1.72
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.9% | ||
| ROE | 14.09% | ||
| ROCE | 9.55% | ||
| ROIC | 7.59% | ||
| ROICexc | 8.76% | ||
| ROICexgc | 20.16% | ||
| OM | 15.8% | ||
| PM (TTM) | 9.1% | ||
| GM | 54.02% | ||
| FCFM | 2.29% |
ROA(3y)4.55%
ROA(5y)4.81%
ROE(3y)10.72%
ROE(5y)11.21%
ROIC(3y)7.51%
ROIC(5y)8.04%
ROICexc(3y)8.78%
ROICexc(5y)9.36%
ROICexgc(3y)21.39%
ROICexgc(5y)20.4%
ROCE(3y)9.45%
ROCE(5y)10.11%
ROICexcg growth 3Y28.22%
ROICexcg growth 5Y5.14%
ROICexc growth 3Y32.37%
ROICexc growth 5Y-1.8%
OM growth 3Y24.43%
OM growth 5Y5.91%
PM growth 3Y-0.56%
PM growth 5Y9.58%
GM growth 3Y4.96%
GM growth 5Y3.61%
F-Score5
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.39 | ||
| Debt/FCF | 39.37 | ||
| Debt/EBITDA | 3.76 | ||
| Cap/Depr | 49.14% | ||
| Cap/Sales | 3.96% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 26.17% | ||
| Profit Quality | 25.13% | ||
| Current Ratio | 3.49 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z | 2.69 |
F-Score5
WACC8.22%
ROIC/WACC0.92
Cap/Depr(3y)95.03%
Cap/Depr(5y)74.64%
Cap/Sales(3y)8.07%
Cap/Sales(5y)6.68%
Profit Quality(3y)138.01%
Profit Quality(5y)129.47%
High Growth Momentum
Growth
EPS 1Y (TTM)11.48%
EPS 3Y19.2%
EPS 5Y10.74%
EPS Q2Q%13.13%
EPS Next Y16.5%
EPS Next 2Y15.78%
EPS Next 3Y15.56%
EPS Next 5Y17.65%
Revenue 1Y (TTM)9.85%
Revenue growth 3Y14.57%
Revenue growth 5Y6.23%
Sales Q2Q%8.59%
Revenue Next Year7.65%
Revenue Next 2Y5.36%
Revenue Next 3Y6.59%
Revenue Next 5Y8.79%
EBIT growth 1Y16.93%
EBIT growth 3Y42.56%
EBIT growth 5Y12.51%
EBIT Next Year51.8%
EBIT Next 3Y19.37%
EBIT Next 5YN/A
FCF growth 1Y-73.25%
FCF growth 3Y17.16%
FCF growth 5Y23.43%
OCF growth 1Y-67.26%
OCF growth 3Y18.65%
OCF growth 5Y2.67%